0000950170-24-043502.txt : 20240410
0000950170-24-043502.hdr.sgml : 20240410
20240410205027
ACCESSION NUMBER: 0000950170-24-043502
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240408
FILED AS OF DATE: 20240410
DATE AS OF CHANGE: 20240410
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FRIEDMAN PAUL A
CENTRAL INDEX KEY: 0001236927
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33277
FILM NUMBER: 24836949
MAIL ADDRESS:
STREET 1: C/O INCYTE CORPORATION
STREET 2: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001157601
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BARR HARBOR DRIVE, SUITE 400
CITY: WEST CONSHOHOCKEN
STATE: PA
ZIP: 19428
BUSINESS PHONE: 404-380-9263
MAIL ADDRESS:
STREET 1: 200 BARR HARBOR DRIVE, SUITE 400
CITY: WEST CONSHOHOCKEN
STATE: PA
ZIP: 19428
FORMER COMPANY:
FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20010815
4
1
ownership.xml
4
X0508
4
2024-04-08
0001157601
MADRIGAL PHARMACEUTICALS, INC.
MDGL
0001236927
FRIEDMAN PAUL A
C/O MADRIGAL PHARMACEUTICALS, INC.
200 BARR HARBOR DRIVE, SUITE 400
WEST CONSHOHOCKEN
PA
19428
true
false
false
false
true
Common Stock
2024-04-08
4
M
false
26270
9.45
A
212005
D
Common Stock
2024-04-08
4
S
false
1441
242.9523
D
210564
D
Common Stock
2024-04-08
4
S
false
3730
244.1197
D
206834
D
Common Stock
2024-04-08
4
S
false
5663
244.8607
D
201171
D
Common Stock
2024-04-08
4
S
false
2078
245.7126
D
199093
D
Common Stock
2024-04-08
4
S
false
5028
246.9590
D
194065
D
Common Stock
2024-04-08
4
S
false
3464
247.7601
D
190601
D
Common Stock
2024-04-08
4
S
false
4866
248.5907
D
185735
D
Common Stock
655540
I
By SQN LLC
Stock Option (Right to Buy)
9.45
2024-04-08
4
M
false
26270
0
D
2026-07-22
Common Stock
26270
206256
D
These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.39 to $243.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.43 to $244.42, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.43 to $245.42, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.43 to $246.28, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.45 to $247.43, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.47 to $248.24, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.47 to $248.64, inclusive.
The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The shares underlying this stock option are fully vested and exercisable.
/s/ Mardi Dier, as Attorney-in-Fact
2024-04-10